The Effect of Periodontal Disease Treatment in Patients With Kidney Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03648723 |
|
Recruitment Status :
Completed
First Posted : August 27, 2018
Last Update Posted : August 27, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Periodontal Diseases |
A new branch of periodontology, defined as "medical periodontology," has been proposed that mentioned the bidirectional relationship between periodontal disease and systemic conditions.
In the lights of these informations, the purpose of the present study was to compare the effects of non-surgical periodontal therapy on patients undergoing continous ambulatory peritoneal dialysis(CAPD) due to diabetic nephropathy and non-diabetic. Forty three participants ( 22 Diabetic Nephropathy(DN) group , 21 Non-Diabetic Nephropathy(N-DN) group) were included and divided into the two group; DN group and N-DN group, in the present study.
The following clinical parameters were evaluated at baseline and the end of the study: Plaque index ; Gingival index ; pocket depth (PD) measurements; bleeding on probing (BOP)-percentage of BOP (+) sites; gingival recession (GR)-from the cement-enamel junction to the gingival margin; and clinical attachment level (CAL)-the sum of PD and GR measurements. The Decay-Missing-Filling Index (DMFT) was recorded. Clinical examinations were repeated 6 months following periodontal treatment. All clinical measurements were taken from the mid-buccal and mid-lingual sites and the buccal aspects of the interproximal contact area for the mesial and distal sites of each tooth to the nearest 0.5 mm using a 15 mm periodontal probe at baseline and the 6th months after treatment. All periodontal clinical examinations were performed by one calibrated examiner (FOT). At baseline and 6 months after treatment, fasting venous blood samples were collected from the antecubital fossa by an experienced nurse. Blood samples for TNF- α, IL-6 and PTX-3 were centrifuged, and separated serum and plasma samples were stored at -80◦C until analysis. TNF-α , IL-6 , and PTX-3 serum levels were determined using a commercial solid-phase enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions. Periodontal treatments were performed 2 hours after the patients had their breakfast following the blood sampling. Standard oral hygiene instructions were given to all groups, including interdental plaque control (interdental brushes) and brushing of the dorsum of the tongue twice a day. Oral hygiene control and re-instructions were provided during all visits. After local infiltration, full-mouth scaling and root planning (FM-SRP) was performed by the same investigator with standard periodontal curettes
| Study Type : | Observational |
| Actual Enrollment : | 43 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Prospective |
| Official Title: | The Comparison of the Effect of Periodontal Treatment in Patients With Diabetic and Non Diabetic Nephropathy |
| Actual Study Start Date : | January 10, 2016 |
| Actual Primary Completion Date : | January 10, 2017 |
| Actual Study Completion Date : | May 10, 2017 |
| Group/Cohort |
|---|
|
Diabetic nephropathy
Diabetic nephropathy is defined by macroalbuminuria that is, a urinary albumin excretion of more than 300 mg in a 24-hour collection or macroalbuminuria and abnormal renal function as represented by an abnormality in serum creatinine, or glomerular filtration rate(GFR)
|
|
Non-diabetic nephropathy
This group consisted of diagnosis with nephropathy without diabetes mellitus.
|
- Periodontal disease parameters change [ Time Frame: Examinations were performed at baseline and repeated 6 months following periodontal treatment. Change is determined with at baseline - at 6 months after periodontal treatment. ]pocket depth (mm) evaluation .was performed by periodontal probe.
- Biochemical parameters change [ Time Frame: biochemical parameters were evaluated at baseline and 6 months following periodontal treatment . Change is determined with baseline - 6 months after periodontal treatment. ]TNF-α pg/mL serum levels were evaluated.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 31 Years to 65 Years (Adult, Older Adult) |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- had to have chronic periodontitis
- ≥15 natural teeth
- needed to be >30 years old
Exclusion Criteria:
- History of antibiotic or anti-inflammatory drugs within the previous 6 months
- pregnancy or lactation
- periodontal therapy within 6 months prior to the study
- past or current smoking and alcohol consumption
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03648723
| Principal Investigator: | Zekeriya Taşdemir | TC Erciyes University |
| Responsible Party: | Zekeriya Tasdemir, Principal investigator, TC Erciyes University |
| ClinicalTrials.gov Identifier: | NCT03648723 |
| Other Study ID Numbers: |
Ztasdemir |
| First Posted: | August 27, 2018 Key Record Dates |
| Last Update Posted: | August 27, 2018 |
| Last Verified: | August 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Periodontal Diseases Mouth Diseases Stomatognathic Diseases |

